- Nov 13, 2017 – Nomination Committee appointed in respect of AGM 2018 in Alligator Bioscience AB
- Nov 7, 2017 – Results from Alligator Bioscience’s clinical phase I study support further clinical development of ADC-1013
- Oct 25, 2017 – Alligator Bioscience AB Interim Report January-September 2017
- Nov 20, 2017 - Medicon Valley Alliance (MVA) Oncology Network Meeting – an evening with Alligator Bioscience
- Nov 24, 2017 - Redeye Life Science Seminar, Stockholm
- Dec 5, 2017 - Carnegie Healthcare Day, New York
Alligator Bioscience has a broad project portfolio with several antibody-based immuno-oncology candidates. The company’s most advanced project, ADC-1013, in clinical Phase I being developed with partner Janssen Biotech, and the preclinical product candidates ATOR-1015, ATOR-1017, och ALG.APV-527.